LXW7 (TFA)
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3].
Product Specifications
UNSPSC
12352209
Target
Integrin
Type
Peptides
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lxw7-tfa.html
Purity
98.44
Solubility
H2O
Smiles
O=C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@H](CC(O)=O)C(N[C@@H]1C(C)C)=O)=O)=O)=O)=O)[C@@H](CSSC[C@H](C(N)=O)NC1=O)N.OC(C(F)(F)F)=O
Molecular Formula
C31H49F3N12O14S2
Molecular Weight
934.92
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog